Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Non-cash Items (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Non-cash Items data on record, last reported at $33.3 million in Q3 2025.

  • For Q3 2025, Non-cash Items rose 570.78% year-over-year to $33.3 million; the TTM value through Sep 2025 reached $33.3 million, up 570.78%, while the annual FY2024 figure was $4.9 million, 71.63% down from the prior year.
  • Non-cash Items reached $33.3 million in Q3 2025 per AMPH's latest filing, up from $20.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $304.8 million in Q2 2023 and bottomed at $500000.0 in Q2 2021.
  • Average Non-cash Items over 5 years is $51.0 million, with a median of $6.4 million recorded in 2023.
  • Peak YoY movement for Non-cash Items: tumbled 98.64% in 2021, then surged 27633.0% in 2022.
  • A 5-year view of Non-cash Items shows it stood at $500000.0 in 2021, then skyrocketed by 17305.0% to $87.0 million in 2022, then plummeted by 80.35% to $17.1 million in 2023, then crashed by 71.63% to $4.9 million in 2024, then soared by 586.94% to $33.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $33.3 million in Q3 2025, $20.0 million in Q2 2025, and $5.0 million in Q1 2025.